Review of pharmacogenomics of psychiatric comorbidities in autism spectrum disorder
Approximately 70% of individuals diagnosed with autism spectrum disorder (ASD) receive at least one psychotropic medication to treat comorbidities. However, the response to treatment with these drugs is far from satisfactory, with 30-50% of treated patients not responding adequately or developing severe and long-lasting side effects. There is strong evidence of the clinical utility of pharmacogenetics for the personalization of antipsychotic and antidepressant treatments in adult populations. However, the use of pharmacogenetic interventions for the personalization of treatment in ASD populations is minimal. The aim of this review is to summarize the findings of pharmacogenetic studies conducted in subjects with ASD and illustrate their utility in the personalization of treatment with psychoactive drugs in this population group.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
Pharmacogenomics - 24(2023), 14 vom: 28. Sept., Seite 781-791 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Alvarez, Aida [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antidepressants |
|---|
| Anmerkungen: |
Date Revised 23.10.2023 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.2217/pgs-2023-0134 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362639124 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362639124 | ||
| 003 | DE-627 | ||
| 005 | 20231226091644.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/pgs-2023-0134 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1208.xml |
| 035 | |a (DE-627)NLM362639124 | ||
| 035 | |a (NLM)37767654 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Alvarez, Aida |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Review of pharmacogenomics of psychiatric comorbidities in autism spectrum disorder |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 23.10.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Approximately 70% of individuals diagnosed with autism spectrum disorder (ASD) receive at least one psychotropic medication to treat comorbidities. However, the response to treatment with these drugs is far from satisfactory, with 30-50% of treated patients not responding adequately or developing severe and long-lasting side effects. There is strong evidence of the clinical utility of pharmacogenetics for the personalization of antipsychotic and antidepressant treatments in adult populations. However, the use of pharmacogenetic interventions for the personalization of treatment in ASD populations is minimal. The aim of this review is to summarize the findings of pharmacogenetic studies conducted in subjects with ASD and illustrate their utility in the personalization of treatment with psychoactive drugs in this population group | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a antidepressants | |
| 650 | 4 | |a autism spectrum disorder | |
| 650 | 4 | |a personalized medicine antipsychotic | |
| 650 | 4 | |a pharmacogenetics | |
| 650 | 4 | |a review | |
| 700 | 1 | |a Bote, Valentin |e verfasserin |4 aut | |
| 700 | 1 | |a Lamborena, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Medina, Raquel |e verfasserin |4 aut | |
| 700 | 1 | |a Serra-LLovich, Alexandre |e verfasserin |4 aut | |
| 700 | 1 | |a Hervas, Amaia |e verfasserin |4 aut | |
| 700 | 1 | |a Arranz, Maria J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pharmacogenomics |d 2000 |g 24(2023), 14 vom: 28. Sept., Seite 781-791 |w (DE-627)NLM111671396 |x 1744-8042 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2023 |g number:14 |g day:28 |g month:09 |g pages:781-791 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2217/pgs-2023-0134 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2023 |e 14 |b 28 |c 09 |h 781-791 | ||